Enfortumab vedotin
- Generic Name
- Enfortumab vedotin
- Brand Names
- Padcev
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1346452-25-2
- Unique Ingredient Identifier
- DLE8519RWM
- Background
Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to bren...
- Indication
Enfortumab vedotin is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting. Enfortumab vedoti...
- Associated Conditions
- Locally Advanced Urothelial Cancer, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Urothelial Cancer
- Associated Therapies
- -
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 219
- Registration Number
- NCT03219333
- Locations
- 🇺🇸
Johns Hopkins Medical Center, Baltimore, Maryland, United States
🇺🇸James Cancer Hospital / Ohio State University, Columbus, Ohio, United States
🇺🇸University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 19
- Registration Number
- NCT03070990
- Locations
- 🇯🇵
Site JP00005, Sendai, Miyagi, Japan
🇯🇵Site JP00003, Tsukuba, Ibaraki, Japan
🇯🇵Site JP00008, Suita, Osaka, Japan
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
- Conditions
- Interventions
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 213
- Registration Number
- NCT02091999
- Locations
- 🇺🇸
Site US00020, Pittsburgh, Pennsylvania, United States
🇺🇸Site US00021, Las Vegas, Nevada, United States
🇺🇸Site US00013, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.